interleukin-12-transduced acute myeloid leukemia cell vaccine

The interleukin-12-transduced acute myeloid leukemia cell vaccine is an experimental cancer immunotherapy designed to treat acute myeloid leukemia (AML). It consists of AML cells that have been genetically modified using viral vectors, such as the murine stem cell virus (MSCV) or lentiviral vectors, to express the p35 and p40 subunits of interleukin-12 (IL-12). IL-12 is a potent heterodimeric cytokine that facilitates the interplay between T cells and antigen-presenting cells. The vaccine utilizes lethally irradiated modified leukemia cells to provide a sustained, local release of IL-12 at the site of administration. This paracrine secretion stimulates a robust immune response, primarily mediated by CD8+ cytotoxic T lymphocytes (CTLs) and the induction of interferon-gamma (IFN-γ), which enhances the expression of MHC and costimulatory molecules (like B7.1 and B7.2) on the leukemia cells. Preclinical studies indicate that this approach can eliminate minimal residual disease and establish long-lasting, leukemia-specific protective immunity.

Other names

IL-12-transduced AML cell vaccineIL12-transduced AML cell vaccineIL 12-transduced AML cell vaccineIL-12-expressing AML cell vaccineIL12-expressing AML cell vaccineIL 12-expressing AML cell vaccineinterleukin-12-transduced AML cell vaccineinterleukin12-transduced AML cell vaccineinterleukin 12-transduced AML cell vaccine